|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009647,
umls-concept:C0013018,
umls-concept:C0014822,
umls-concept:C0032854,
umls-concept:C0040808,
umls-concept:C0086418,
umls-concept:C0087111,
umls-concept:C0205251,
umls-concept:C0206153,
umls-concept:C0333678,
umls-concept:C0681842,
umls-concept:C0871261,
umls-concept:C1515895,
umls-concept:C1561558,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2323499,
umls-concept:C2911692
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2006-6-26
|
|
pubmed:abstractText |
After allogeneic hematopoietic stem cell transplantation with nonmyeloablative conditioning (NMHCT), many patients experience prolonged anemia and require red blood cell (RBC) transfusions. We enrolled 60 consecutive patients undergoing NMHCT in a phase II trial to determine the optimal utilization of recombinant human erythropoietin (rHuEPO) therapy in this setting.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0301-472X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
34
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
841-50
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16797411-Adult,
pubmed-meshheading:16797411-Aged,
pubmed-meshheading:16797411-Chimera,
pubmed-meshheading:16797411-Erythrocyte Transfusion,
pubmed-meshheading:16797411-Erythropoietin,
pubmed-meshheading:16797411-Female,
pubmed-meshheading:16797411-Humans,
pubmed-meshheading:16797411-Male,
pubmed-meshheading:16797411-Middle Aged,
pubmed-meshheading:16797411-Recombinant Proteins,
pubmed-meshheading:16797411-Stem Cell Transplantation,
pubmed-meshheading:16797411-Transplantation, Homologous,
pubmed-meshheading:16797411-Transplantation Conditioning
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: low donor chimerism predicts for poor response.
|
|
pubmed:affiliation |
Department of Medicine, Division of Hematology; University of Liege, Liege, Belgium.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
